Elicio Therapeutics Announced The Publication Of Data From The Phase 1 (AMPLIFY-201) Study Of ELI-002 2P In Solid Tumors In Nature Medicine
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics has published data from its Phase 1 AMPLIFY-201 study of ELI-002 2P in solid tumors in Nature Medicine. The results show that ELI-002, as a monotherapy, induced strong and lasting T cell responses and led to tumor biomarker reduction in 84% of patients. This correlated with a median relapse-free survival of 16.3 months. A Phase 2 trial for ELI-002 in pancreatic ductal adenocarcinoma is set to begin in early 2024.
January 09, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elicio Therapeutics' positive Phase 1 study results for ELI-002 could lead to increased investor confidence and potential stock price appreciation in the short term.
The publication of positive data from the Phase 1 study of ELI-002 in a reputable journal like Nature Medicine is a significant milestone for Elicio Therapeutics. The observed efficacy in terms of T cell response and tumor biomarker reduction, along with the planned Phase 2 trial, are likely to be viewed positively by investors. This could lead to increased demand for ELTX shares in the short term, potentially driving up the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100